ClinicalTrials.gov record
Recruiting Phase 1 Interventional

Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors

ClinicalTrials.gov ID: NCT06914479

Public ClinicalTrials.gov record NCT06914479. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Study of a Combined Cytotoxic and Immune-Stimulatory Therapy in Pediatric and Young Adult Patients With Recurrent, Primary Malignant Brain Tumors

Study identification

NCT ID
NCT06914479
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Enrollment
11 participants

Conditions and interventions

Interventions

  • Ad-hCMV-Flt3L Genetic
  • Ad-hCMV-TK Genetic
  • Biospecimen Collection Procedure
  • Magnetic Resonance Imaging Procedure
  • Survey Administration Other
  • Tumor Resection Procedure
  • Valacyclovir Drug

Genetic · Procedure · Other + 1 more

Eligibility (public fields only)

Age range
3 Years to 39 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2026
Primary completion
May 31, 2031
Completion
May 31, 2031
Last update posted
Mar 10, 2026

2026 – 2031

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
University of Michigan Comprehensive Cancer Center Ann Arbor Michigan 48109 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06914479, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 10, 2026 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06914479 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →